# A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.

> **NCT00738257** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 126 (actual)

## Conditions studied

- Bone Loss

## Interventions

- **DRUG:** Pamidronate

## Key facts

- **NCT ID:** NCT00738257
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2010-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00738257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00738257, "A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00738257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*